<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418418</url>
  </required_header>
  <id_info>
    <org_study_id>TYH 6220</org_study_id>
    <nct_id>NCT00418418</nct_id>
  </id_info>
  <brief_title>Combined CABG and Stem-Cell Transplantation for Heart Failure</brief_title>
  <official_title>Combined CABG and Stem-Cell Transplantation for Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective double blind trial of intraoperative transmyocardial bone
      marrowâˆ’derived mesenchymal cell transplantation vs placebo in patients with low left
      ventricular ejection fraction scheduled to coronary bypass operation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of symptomatic heart failure in general population is up to 2% and the
      prevalence increases rapidly with age. Half of the patients with symptomatic heart failure
      will die within 4 years of diagnosis.The purpose of this study is to examine the effect of
      bone marrow-derived stem cell transplantation in left ventricular ejection fraction.

      Consecutive patients with systolic heart failure (n=60), with ischemic coronary heart
      disease, scheduled to by-pass-operation (CABG) will be collected from cardiovascular
      laboratory and outpatient clinic of Helsinki University Central Hospital. Patients should
      have heart failure with ejection fraction between 15 to 45%. Randomly patients are selected
      to receive a stem cell transplantation with best possible heart failure medication, or
      without cell transplantation. In this study, 30 patients are receiving bone marrow
      transplantation, and 30 patients are serving as a control population. All patients will
      receive CABG.The study will be carried out with randomized, double blind techniques for one
      year. Randomization (in blocks) will be based on a table of random numbers.Bone marrow and
      patients own serum will be blinded by using colored syringe, so that the doctor transfusing
      the sample, will not be able to know the nature of the sample. From all patients, a right
      atrial biopsy will be collected for assessment of autologous cardiac stem cells. Also sample
      of pericardial fluid will be collected for measures of growth factors.

      Comparisons: Preoperatively, patients will be imagined by cardiac ultrasound, cardiac MRI,
      cardiac PET and SPECT. Serum pro-BNB samples will be collected. Postoperatively at 3 months
      and 6 months pro-BNB and cardiac ultrasound will be evaluated. At one year cardiac
      ultrasound, cardiac MRI, cardiac PET and SPECT will be reassessed.

      Heart failure and coronary artery disease treatments beside the transplantation will be
      optimized according to the judgment of the doctors of the outpatients clinic. Primary
      endpoint of the study is the change of ejection fraction in MRI images.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Does a bone marrow transplantation therapy increase the ejection fraction of the heart measured with MRI, when compared with placebo treatment?</measure>
    <time_frame>1 year after the transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Does a bone marrow transplantation therapy increase any cardiac function parameter measured by a an echocardiography, MRI or PET ischemia area, when compared with no treatment group?</measure>
    <time_frame>6 months and 1 year after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does a bone marrow transplantation therapy improve BNP-value?</measure>
    <time_frame>3kk, 6 months and 1 year after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does a bone marrow transplantation therapy decrease hospitalization or the days stayed in hospital?</measure>
    <time_frame>primary hospital stay after the transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does pericardial fluid growth factor concentrations correlate to left ventricular function improvement?</measure>
    <time_frame>up to 1 year after the translantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does autologous cardiac stem cell quality correlate to left ventricular function improvement?</measure>
    <time_frame>3kk, 6 months and 1 year after the transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient group receiving the stem cell injections during the CABG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patient group receiving autologous serum injections during the CAGB operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coronary bypass operation</intervention_name>
    <description>Coronary bypass operation is performed via sternotomy during cardiac arrest.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>CABG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow aspiration (crista iliaca)</intervention_name>
    <description>The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Stem cell harvest</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramyocardial mesenchymal stem cell transplantation</intervention_name>
    <description>During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Stem cell therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramyocardial injection of autologous serum</intervention_name>
    <description>Intramyocardial injection of autologous serum is injected during cardiac arrest</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Stem cell control therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General (patients must have all)

               -  Symptomatic heart failure.

               -  Scheduled to CABG

               -  Be 18 to 75 years of age

               -  Informed Consent obtained

          -  Heart Failure Presentation

               -  Patients of either gender, who has evaluated in cardiovascular laboratory and
                  scheduled to CABG with moderate heart failure, will be eligible

               -  NYHA II-IV symptoms

               -  Left ventricular ejection fraction in screening echocardiography 15 to 45%.

               -  Optimal heart failure medication and coronary medication before operation,
                  containing at least two heart failure drugs: must have ACE-inhibitor, or AT II
                  blocker, and/or b-blocker together with diuretics, digitalis or aldosterone
                  antagonist, and coronary medication: a statin and anticoagulation, either aspirin
                  or clopidogrel.

        Exclusion Criteria:

          -  Heart failure due to left ventricular outflow track obstruction (valve problem or
             HOCM)

          -  History of life-threatening ventricular arrhythmias or resuscitation, condition which
             may be repeatable or implanted ICD.

          -  Stroke or other disabling condition with in 3 months before screening

          -  Contraindications to coronary angiogram or MRI

          -  Other serious disease limiting life expectancy

          -  Participation in an other clinical trial

          -  Severe valve disease: mitral, aortic, tricuspid or pulmonic stenosis / insufficiency

          -  Scheduled valve operation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari Harjula, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiothoracic Surgery, Helsinki University MeilahtiHospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ari Harjula, MD,PhD</last_name>
    <phone>+3585064814</phone>
    <email>ari.harjula@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tommi PÃ¤tilÃ¤, MD</last_name>
    <phone>+358504272291</phone>
    <email>tommi.patila@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiothoracic Surgery, Meilahti Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029-HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Harjula, MD, PhD</last_name>
      <phone>+5042764814</phone>
      <email>ari.harjula@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Tommi PÃ¤tilÃ¤, MD, PhD</last_name>
      <phone>+358504272291</phone>
      <email>tommi.patila@hus.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Ari Harjula, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tommi PÃ¤tilÃ¤, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sinisalo Juha, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antti Vento, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mika Laine, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pekka HÃ¤mmÃ¤inen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esko Kankuri, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reino PÃ¶yhiÃ¤, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raili Suojaranta-Ylinen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aapo Ahonen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorma Sipponen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markku Kupari, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Riitta Alitalo, MD; PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <last_update_submitted>August 18, 2008</last_update_submitted>
  <last_update_submitted_qc>August 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Reijo Haapiainen</name_title>
    <organization>Helsinki University Hospital</organization>
  </responsible_party>
  <keyword>Cell transplantation</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Clinical trials</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

